drugset / Trial / NCT00000588
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
Phase 2
Completed
120 enrolled
Case Western Reserve University
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
To demonstrate the safety and effectiveness of orally-administered pyridoxal isonicotinoyl hydrazone (PIH) for the chronic treatment of iron overload.
Timeline
- Start
- 1989-06-05
- Primary completion
- 1993-03-31
- Completion
- 1995-03-31
Publications
- Background Brittenham GM. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration. Ann N Y Acad Sci. 1990;612:315-26. doi: 10.1111/j.1749-6632.1990.tb24319.x. No abstract available.
- Background Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol. 1990 Apr;27(2):112-6. No abstract available.
- Background Nathan DG. An orally active iron chelator. N Engl J Med. 1995 Apr 6;332(14):953-4. doi: 10.1056/NEJM199504063321411. No abstract available.
- Background Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995 Apr 6;332(14):918-22. doi: 10.1056/NEJM199504063321404.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridoxal Isonicotinoyl Hydrazone | Small molecule | — | Oral |